Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
A Look at AtriCure Inc (ATRC) After 6.0% Decline -- GF Value $39.32 vs Price $37.76
07:45pm, Friday, 31'st Jul 2026
On July 31, 2026, AtriCure Inc (ATRC) shares fell 6.0% today, bringing the current price to $37.76. This price is within a 52-week range of $25.36 to $43.18, re
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
09:40pm, Thursday, 23'rd Jul 2026
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
08:01pm, Thursday, 23'rd Jul 2026
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
06:27pm, Thursday, 23'rd Jul 2026
AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.
AtriCure Q2 Earnings Call Highlights
06:07pm, Thursday, 23'rd Jul 2026
AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appen
AtriCure Reports Second Quarter 2026 Financial Results
04:01pm, Thursday, 23'rd Jul 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Announce Second Quarter 2026 Financial Results
08:00am, Thursday, 02'nd Jul 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
08:41am, Friday, 19'th Jun 2026
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Do Options Traders Know Something About AtriCure Stock We Don't?
10:47am, Thursday, 11'th Jun 2026
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:52am, Wednesday, 10'th Jun 2026
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
08:00am, Wednesday, 27'th May 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:30pm, Tuesday, 12'th May 2026
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
03:10pm, Tuesday, 12'th May 2026
AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
02:11am, Wednesday, 06'th May 2026
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings
09:31pm, Tuesday, 05'th May 2026
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
